1. Home
  2. CRSP vs ESNT Comparison

CRSP vs ESNT Comparison

Compare CRSP & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$50.24

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Logo Essent Group Ltd.

ESNT

Essent Group Ltd.

HOLD

Current Price

$64.38

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
ESNT
Founded
2013
2008
Country
Switzerland
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.9B
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
CRSP
ESNT
Price
$50.24
$64.38
Analyst Decision
Buy
Buy
Analyst Count
20
7
Target Price
$71.95
$68.71
AVG Volume (30 Days)
1.8M
741.0K
Earning Date
02-11-2026
02-13-2026
Dividend Yield
N/A
1.97%
EPS Growth
N/A
N/A
EPS
N/A
6.87
Revenue
$38,337,000.00
$1,263,558,000.00
Revenue This Year
N/A
$3.55
Revenue Next Year
$1,376.73
$0.85
P/E Ratio
N/A
$9.17
Revenue Growth
N/A
2.04
52 Week Low
$30.04
$51.61
52 Week High
$78.48
$67.09

Technical Indicators

Market Signals
Indicator
CRSP
ESNT
Relative Strength Index (RSI) 40.76 56.54
Support Level $49.10 $60.92
Resistance Level $53.00 $63.80
Average True Range (ATR) 3.12 1.33
MACD -0.48 0.30
Stochastic Oscillator 12.40 85.14

Price Performance

Historical Comparison
CRSP
ESNT

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About ESNT Essent Group Ltd.

Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.

Share on Social Networks: